NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 6 - Endocrine system 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing
06.05.02 Posterior pituitary hormones and antagonists
NICE CG111: Nocturnal enuresis (NICE 2010)
06.05.02 Posterior pituitary hormones
06.05.02 Antidiuretic hormone antagonists
NICE CG111: Nocturnal enuresis (NICE 2010)

Tolvaptan (Jinarc® / Teva)
(15/45mg, 30/60mg, 30/90mg tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be used in accordance with the following NICE TA(s) only:

BNF BNFc SPC
NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease

Tolvaptan (Samsca®)
(7.5mg, 15mg, 30mg Tablets)

RED
Restricted Drug Restricted

Hyponatraemia due to lung cancer is funded by NHSE.

FOR SIADH PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Tolvaptan is recommended as an option for treating hyponatraemia secondary
to SIADH for patients who do not require chemotherapy

  • with proven SIADH with serum sodium symptoms, where fluid restriction and a one week trial of demeclocycline treatment have failed or are contra-indicated.
  • Course of treatment should not exceed 10 days.
  • Treatment should be initiated in secondary care and monitored by a specialist.
  • Prescribing should remain in secondary care. Prescribing in primary care is
    not recommended.
  • Trusts must notify ICBs on initiation of treatment and provide clinical and
    outcome data.
BNF BNFc SPC
JPC bulletin 261: Tolvaptan (Samsca® Brand) tablets for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients not requiring chemotherapy (March 18) NHS England: Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.